Hemophilus influenzae type b (Hib) vaccine: An effective control strategy in India
Human Vaccines · 2011-11 · 7 (11) · 1158-1160
DOI: 10.4161/hv.7.11.17683 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Vaccines, online erschienen am 27.10.2014. Verfasst von Ramesh Verma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine, Pt. B.D. Sharma PGIMS, Rohtak, India. dr.rameshverma@yahoo.co.in. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Haemophilus influenzae type b (Hib) is an encapsulated, non-motile and non-spore-forming Gram-negative coccobacillus which causes severe pneumonia, meningitis and other life threatening illnesses. Hib disease affects almost exclusively (95%) children aged less than 5 years throughout the world. The mean age of onset is 6-24 months after which it declines gradually until age 5 years. The World Health Organization (WHO) estimates that Hib is responsible for 3 million cases of serious illnesses and approximately 386,000 deaths worldwide each year in children aged under 5 years. In the latest position paper on Hib vaccine, WHO recommended the inclusion of Hib conjugate vaccines in all routine infant immunization programs without waiting for local disease-burden data. The WHO and the Global Alliance for Vaccine Immunization (GAVI) have been working to expand supplies of Hib vaccine, reduce vaccine cost, and assist especially low-income countries with vaccine introduction. Hib vaccine is safe, highly effective and readily available in the market. Hib vaccine has been shown to be > 95% efficacious in diverse populations around the world. Globally, hundreds of millions of doses of Hib vaccine have been administered in the last 2 decades. More than 160 countries are using Hib vaccine in national immunization programmes and around 25 countries planning to introduce. Hib vaccination fits into the India's national immunization schedule.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Community Medicine, Pt. B.D. Sharma PGIMS, Rohtak, India. dr.rameshverma@yahoo.co.in
Zitieren
APA
Verma, R., Khanna, P., Chawla, S., Bairwa, M., Prinja, S., & Rajput, M. (2011). Hemophilus influenzae type b (Hib) vaccine: An effective control strategy in India. Human Vaccines, 7(11), 1158-1160. https://doi.org/10.4161/hv.7.11.17683
Vancouver
Verma R, Khanna P, Chawla S, Bairwa M, Prinja S, Rajput M. Hemophilus influenzae type b (Hib) vaccine: An effective control strategy in India. Human Vaccines. 2011;7(11):1158-1160. doi:10.4161/hv.7.11.17683
BibTeX
@article{Verma2011,
author = {Verma, Ramesh and Khanna, Pardeep and Chawla, Suraj and Bairwa, Mohan and Prinja, Shankar and Rajput, Meena},
title = {Hemophilus influenzae type b (Hib) vaccine: An effective control strategy in India},
journal = {Human Vaccines},
year = {2011},
volume = {7},
number = {11},
pages = {1158--1160},
doi = {10.4161/hv.7.11.17683}
}
EUVIMED